Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations.
Author
Simons, GwendaCaplan, Joshua
DiSantostefano, Rachael L
Veldwijk, Jorien
Englbrecht, Matthias
Bywall, Karin Schölin
Kihlbom, Ulrik
Raza, Karim
Falahee, Marie
Affiliation
University of Birmingham; Janssen Pharmaceuticals; School of Health Policy & Management, Erasmus University Rotterdam; University Medical Center Utrecht; Uppsala University; Sandwell and West Birmingham NHS TrustPublication date
2022-02-22Subject
Rheumatology
Metadata
Show full item recordAbstract
Treatments used for rheumatoid arthritis (RA) are under investigation for their efficacy to prevent RA in at risk groups. It is therefore important to understand treatment preferences of those at risk. We systematically reviewed quantitative preference studies of drugs to treat, or prevent RA, to inform the design of further studies and trials of RA prevention. Stated preference studies for RA treatment or prevention were identified through a search of five databases. Study characteristics and results were extracted, and the relative importance of different types of treatment attributes was compared across populations. Twenty three studies were included 20 of RA treatments (18 of patients; 2 of the general public) and 3 prevention studies with first-degree relatives (FDRs). Benefits, risks, administration method and cost (when included) were important determinants of treatment choice. A benefit was more important than a risk attribute in half of the studies of RA treatment that included a benefit attribute and 2/3 studies of RA prevention. There was variability in the relative importance of attributes across the few prevention studies. In studies with non-patient participants, attributes describing confidence in treatment effectiveness/safety were more important determinants of choice than in studies with patients. Most preference studies relating to RA are of treatments for established RA. Few studies examine preferences for treatments to prevent RA. Given intense research focus on RA prevention, additional preference studies in this context are needed. Variation in treatment preferences across different populations is not well understood and direct comparisons are needed.Citation
Simons G, Caplan J, DiSantostefano RL, Veldwijk J, Englbrecht M, Bywall KS, Kihlbom U, Raza K, Falahee M. Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations. Arthritis Res Ther. 2022 Feb 22;24(1):55. doi: 10.1186/s13075-021-02707-4.Type
ArticlePMID
35193653Journal
Arthritis Research & TherapyPublisher
BMCae974a485f413a2113503eed53cd6c53
10.1186/s13075-021-02707-4